Two cases of metastatic NSCLC harboring NTRK3 rearrangement from TRIDENT-1 study achieved durable responses to repotrectinib, with one being NTRK-TKI naive and one with previous entrectinib resistance mediated by G623R mutation (82). Here, NTRK3 is linked to non-small cell lung carcinoma.